China Journal of Leprosy and Skin Diseases ›› 2020, Vol. 36 ›› Issue (4): 219-223.doi: 10.12144/zgmfskin202004219

Previous Articles     Next Articles

Reactive capillary hemangiomas caused by PD-1 inhibitor (Calerizumab) : a report of three cases and literature review

LONG Fangyuan1*, HE Fang1*, TU Jie1, ZHANG Zhiqin1, XU Jiali2, YIN Zhiqiang1   

  1. 1 Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; 
    2 Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
    *Co-first author
  • Online:2020-04-15 Published:2020-04-27
  • Contact: XU Jiali, E-mail: scarlett0830@sina.com; YIN Zhiqiang, E-mail: yinzhiqiang@njmu.edu.cn

Abstract: Three patients with reactive capillary hemangiomas caused by PD-1 inhibitor (calerizumab) treated for solid tumorsed are reported and the related literature is reviewed. After the first treatment with calerizumab, the patients with solid tumors gradually developed to capillary hemangiomas. The lesions were red-nevus-like, pearl-like or mulberry-like, and were most on the head and neck, trunk, and extremities. Dermoscopic examination revealed multiple, small, well-demarcated, red lacunae scattered throughout the lesion on a background of red-whitish homogenous color. The diagnosis of reactive capillary hemangiomas was made.

Key words: calerizumab, reactive capillary hemangiomas